On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s disease or for patients with mild cognitive impairment. This drug, lecanemab, moderately slows the rate of cognitive decline in a way that is noticeable to patients. The Hospital Universitari General de Catalunya, through the Clinical Research Unit (UDIC) led by…
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate a drug to treat agitation in Alzheimer’s patients. As reported by the hospital in a statement, the health center participates in the clinical trial 20AVP-786-307, which evaluates the tolerability of AVP786 to treat agitation in patients with Alzheimer’s. This is…
We have reached the first position, in December 2019, in the international inclusion of patients in the trial with sublingual apomorphine and motor blocks in Parkinson. We are also leading the national inclusion of patients in the Clarity AD trial (monoclonal anti-amyloid antibody in early Alzheimer) Finally, in the Graduate trial (monoclonal subcutaneous in Alzheimer)…
Grifols has reported to the press the positive result of the AMBAR trial in patients with Alzheimer’s disease in a moderate phase. Our unit (located in the General University Hospital of Catalonia) participated in this phase II clinical trial. Patients were treated with several plasmapheresis and albumin replacement, with or without immunoglobulins administration, compared to…
On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated Aducanumab (an anti-alpha synuclein monoclonal antibody) in early Alzheimer’s disease. Efficacy in slowing cognitive impairment was demonstrated (measured with the CDR-SB, MMSE, ADAS-cog and ADCS-ADL scales) and a reduction in amyloid…
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to reduce to 67% the selective tests. BARCELONA Given the difficulties of finding an effective treatment to cure Alzheimer’s disease, efforts to prevent the disease multiply. One of the entities that works in this line is the Pasqual Maragall Foundation, which…
Neurology and Neuropsychology team specializes in the evaluation of biomarkers and the early diagnosis of neurodegenerative diseases. World Alzheimer’s Day is this Saturday, September 21, the day on which it is necessary to highlight the importance of the development of the investigations that are being carried out to combat this disease, which does not yet…
The General University Hospital of Catalonia analyzes in two proteins and in a gum bacterium the origin and cure of Alzheimer’s disease through several studies. Like every afternoon of that August of Olympic hangover, José took the hat and went for a walk. But at twenty minutes I didn’t know where I was. That day…
We have initiated a clinical trial to assess the efficacy and safety of a drug that inhibits the proteases of a bacterium (P.gingivalis) that is detected in the brains of Alzheimer’s patients. It is a new approach to this pathology, absolutely different from the rest of ongoing projects. More information at www.gaintrial.com.
We started a phase II / III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage Alzheimer’s disease. It involves a change in the therapeutic target hitherto chosen: the amyloid protein